Nephrology

Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).

Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.

Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.

As the USPSTF considers evidence for updated CKD screening guidance, Garimella discusses gaps in kidney disease detection and what the review should capture.

Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.

Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.

The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.

Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.

Atacicept also stabilized eGFR and matched placebo on safety, with a full FDA approval filing planned for Q4 2026.

A principal healthcare consultant and study co-author shares his own decade-long path to an IgA nephropathy diagnosis and transplant.

ESC and ERA issue the first dedicated guideline on managing cardiovascular disease alongside chronic kidney disease, via a “STAMP on CKD” framework.

A survey of patients with IgA nephropathy shows how nonspecific symptoms and long referral waits delay diagnosis by up to two years.

Alexander Combes, PhD, discusses how kidney organoids could be used to screen and repurpose drugs for acute kidney injury.

Human kidney organoids reveal why proximal tubule cells resist full recovery after AKI, aiding drug screening research.

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

A nephrologist outlines gaps in CKD tracking, medication access, and transplant standards across the carceral health system.

The phase 2 TRANQUILITY trial found the IL-6 antibody pacibekitug produced sustained, dose-dependent reductions in hs-CRP in patients with chronic kidney disease.

The ESC and ERA issued their first joint guideline recommending universal CKD screening and expanded use of risk-modifying therapies in patients with cardiovascular disease.

Laura J. Maursetter, MD, discusses the case for standardized kidney screening protocols, transplant access, and medical education reform for the correctional population.

Cleveland Clinic's Ali Mehdi, MD, MEd, on the limits of current IgA nephropathy risk tools and where phenotyping could take treatment next.

Laura J. Maursetter, MD, discusses why early kidney disease screening and continuity of care are especially critical for justice-involved patients.

Rethinking IgA Nephropathy Risk and Treatment, With Ali Mehdi, MD, MEd

A nephrologist details gaps in tracking CKD screening, labs, and treatment in correctional care.

VISIONARY enrolled 510 high-risk IgAN patients globally. Learn how the trial's design and anti-APRIL mechanism were built to target disease at its root.